المؤلفون: Crouzen, J. A., Petoukhova, A. L., Broekman, M. L. D., Fiocco, M., Fisscher, U. J., Franssen, J. H., Gadellaa-van Hooijdonk, C. G. M., Kerkhof, M., Kiderlen, M., Mast, M. E., van Rij, C. M., Nandoe Tewarie, R., van de Sande, M. A. E., van der Toorn, P. P. G., Vlasman, R., Vos, M. J., van der Voort van Zyp, N. C. M. G., Wiggenraad, R. G. J., Wiltink, L. M., Zindler, J. D.^{Aff1, Aff10, IDs12885023107611_cor20}

المصدر: BMC Cancer. 23(1)

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Lankheet, N A G, Kloth, J S L, Gadellaa-van Hooijdonk, C G M, Cirkel, G A, Mathijssen, R H J, Lolkema, M P J K, Schellens, J H M, Voest, E E, Sleijfer, S, de Jonge, M J A, Haanen, J B A G, Beijnen, J H, Huitema, A D R, Steeghs, N, Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

المساهمون: Medical Oncology

المصدر: British Journal of Cancer, 110(10), 2441-2449. Nature Publishing Group
British Journal of Cancer, 110, 2441-9
British Journal of Cancer, 110(10), 2441. Nature Publishing Group
British Journal of Cancer, 110, 10, pp. 2441-9
British Journal of Cancer

مصطلحات موضوعية: Male, Cancer Research, Indoles, Gastrointestinal Diseases, sunitinib, Salvage therapy, Pilot Projects, urologic and male genital diseases, Neoplasms, Fatigue, Sunitinib, personalised medicine, Middle Aged, pharmacokinetics and pharmacodynamics, female genital diseases and pregnancy complications, Oncology, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], biodistribution/toxicology, Toxicity, Female, Drug, Drug Monitoring, medicine.drug, Adult, medicine.medical_specialty, therapeutic drug monitoring, Urology, Antineoplastic Agents, kinase and phosphatase inhibitors, Drug Administration Schedule, Dose-Response Relationship, Pharmacokinetics, medicine, Humans, Pyrroles, Dosing, Adverse effect, Protein Kinase Inhibitors, Aged, Salvage Therapy, Dose-Response Relationship, Drug, business.industry, Hematologic Diseases, Surgery, Clinical trial, Clinical Study, Feasibility Studies, Trough level, Nervous System Diseases, business

وصف الملف: application/pdf; image/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6004b5de8b4355f31ec2b5fd627915f
https://pure.eur.nl/en/publications/0254e6e9-7a9a-4c29-8cfd-c895f76888fe

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Lankheet NA; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands., Kloth JS; Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands., Gadellaa-van Hooijdonk CG; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Cirkel GA; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Mathijssen RH; 1] Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Lolkema MP; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Schellens JH; 1] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 12, 1066 CX Amsterdam, The Netherlands., Voest EE; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Sleijfer S; 1] Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., de Jonge MJ; 1] Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Haanen JB; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 12, 1066 CX Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands., Huitema AD; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands., Steeghs N; 1] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 12, 1066 CX Amsterdam, The Netherlands.

المصدر: British journal of cancer [Br J Cancer] 2014 May 13; Vol. 110 (10), pp. 2441-9. Date of Electronic Publication: 2014 Apr 15.

نوع المنشور: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Salvage Therapy*, Antineoplastic Agents/*administration & dosage , Indoles/*administration & dosage , Neoplasms/*drug therapy , Protein Kinase Inhibitors/*administration & dosage , Pyrroles/*administration & dosage, Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/blood ; Antineoplastic Agents/pharmacokinetics ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Monitoring ; Fatigue/chemically induced ; Feasibility Studies ; Female ; Gastrointestinal Diseases/chemically induced ; Hematologic Diseases/chemically induced ; Humans ; Indoles/adverse effects ; Indoles/blood ; Indoles/pharmacokinetics ; Male ; Middle Aged ; Neoplasms/enzymology ; Nervous System Diseases/chemically induced ; Pilot Projects ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/blood ; Protein Kinase Inhibitors/pharmacokinetics ; Pyrroles/adverse effects ; Pyrroles/blood ; Pyrroles/pharmacokinetics ; Sunitinib